The Nobori biolimus-eluting stent: update of available evidence

References

• Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65
   PubMed Web of Science ®Google Scholar
• Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95
   PubMed Web of Science ®Google Scholar
• Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19
   PubMed Web of Science ®Google Scholar
• Piccolo R, Cassese S, Galasso G, et al. Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. Atherosclerosis 2011;217:149-57
   PubMed Web of Science ®Google Scholar
• Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010;56:S43-78
   PubMed Web of Science ®Google Scholar
• Centemero MP, Stadler JR. Stent thrombosis: an overview. Expert Rev Cardiovasc Ther 2012;10:599-615
   PubMedGoogle Scholar
• Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009;120:141-9; 1-2
   PubMed Web of Science ®Google Scholar
• Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-9
   PubMed Web of Science ®Google Scholar
• Danzi GB, Chevalier B, Ostojic M, et al. Nobori drug eluting stent system: clinical evidence update. Minerva Cardioangiol 2010;58:599-610
   PubMed Web of Science ®Google Scholar
• Takahashi S, Yamada S, Yasaka Y, et al. Difference of drug-eluting stent expansion between thin strut cobalt chromium platform and thick strut stainless platform in calcified lesions. Eur Heart J 2013;34:548-9
   PubMed Web of Science ®Google Scholar
• Grube E, Hauptmann KE, Buellesfeld L, et al. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention 2005;1:53-7
   PubMedGoogle Scholar
• Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater 2003;5:1-16; discussion 16
   PubMedGoogle Scholar
• Lasprilla AJ, Martinez GA, Lunelli BH, et al. Poly-lactic acid synthesis for application in biomedical devices - a review. Biotechnol Adv 2012;30:321-8
   PubMed Web of Science ®Google Scholar
• Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996;17:93-102
   PubMed Web of Science ®Google Scholar
• Basalus MW, van Houwelingen KG, Ankone M, et al. Scanning electron microscopic assessment of the biodegradable coating on expanded biolimus-eluting stents. EuroIntervention 2009;5:505-10
   PubMed Web of Science ®Google Scholar
• Nakamura M, Otsuka Y, Ueda Y, Mitsudo K. Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects. Cardiovasc Interv Ther 2012;27:24-30
   PubMedGoogle Scholar
• Hagiwara H, Hiraishi Y, Terao H, et al. Vascular responses to a biodegradable polymer (polylactic acid) based biolimus A9-eluting stent in porcine models. EuroIntervention 2012;8:743-51
   PubMed Web of Science ®Google Scholar
• Mori M, Takabatake S, Nakanishi C, et al. Impact of very early endotherialization after Nobori stent implantation on its low frequency of in-stent thrombosis: evidence from super acute examination in a porcine model. Circulation 2013;128:A16428
   Web of Science ®Google Scholar
• Sumida A, Nagai H, Gogas B, et al. Comparison of coronary artery endothelial function after Nobori and Xience V stent implantation in swine model. J Am Coll Cardiol 2012;59:E58
   Google Scholar
• Ostojic M, Sagic D, Jung R, et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv 2008;72:901-8
   PubMed Web of Science ®Google Scholar
• Ostojic M, Sagic D, Beleslin B, et al. First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention 2008;3:574-9
   PubMedGoogle Scholar
• Hamilos MI, Ostojic M, Beleslin B, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008;51:2123-9
   PubMed Web of Science ®Google Scholar
• Pendyala LK, Matsumoto D, Shinke T, et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. JACC Cardiovasc Interv 2012;5:436-44
   PubMed Web of Science ®Google Scholar
• Kadota K, Muramatsu T, Iwabuchi M, et al. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv 2012;80:789-96
   PubMed Web of Science ®Google Scholar
• Kimura T, Muramatsu T, Iwabuchi M, et al. Three year follow up of a randomized comparison of Nobori, biolimus A9 eluting stent(BES) with cypher, sirolimus eluting stent(SES) for coronary revascularization in Japanese population. J Am Coll Cardiol 2012;60:B182
   Web of Science ®Google Scholar
• Chevalier B, Serruys PW, Silber S, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007;2:426-34
   PubMedGoogle Scholar
• Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial–Phase 2. Circ Cardiovasc Interv 2009;2:188-95
   PubMed Web of Science ®Google Scholar
• Danzi GB, Chevalier B, Urban P, et al. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. EuroIntervention 2012;8:109-16
   PubMed Web of Science ®Google Scholar
• Fath-Ordoubadi F, Hildick-Smith D, Carrier D, et al. Six months clinical outcomes in Nobori-STEMI Study. EuroIntervention 2009;5
   PubMed Web of Science ®Google Scholar
• Piccolo R, Cassese S, Galasso G, et al. Sirolimus- versus paclitaxel-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol 2011;146:234-6
   PubMed Web of Science ®Google Scholar
• Piscione F, Piccolo R, Cassese S, et al. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention 2010;5:853-60
   PubMed Web of Science ®Google Scholar
• Iniguez A, Fath-Ordoubadi F, Cebollero IC, et al. Drug-eluting stent with biodegradable polymer in patients with STEMI – short and long term outcomes: data from e-NOBORI and NOBORI 2 trials. J Am Coll Cardiol 2012;60:B167
   PubMed Web of Science ®Google Scholar
• Morice MC, Chevalier B, Tresukosol D, et al. Clinical outcomes of bifurcation stenting in NOBORI 2 study. EuroIntervention 2010;6
   Google Scholar
• Chevalier B, Morice MC, Serra A, et al. Clinical outcomes of chronic total occlusions in NOBORI 2 Study. EuroIntervention 2010;6
   PubMed Web of Science ®Google Scholar
• Santoso T, Tresukosol D, Lim V, et al. Impact of diabetes on DES-success rates and clinical outcomes in NOBORI 2 Study. EuroIntervention 2010;6
   Google Scholar
• Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013;381:661-9
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-91
   PubMed Web of Science ®Google Scholar
• Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402
   PubMed Web of Science ®Google Scholar
• Cassese S, Piccolo R, Galasso G, et al. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. Int J Cardiol 2011;150:84-9
   PubMed Web of Science ®Google Scholar
• Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60
   PubMed Web of Science ®Google Scholar
• Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013;62:181-90
   PubMed Web of Science ®Google Scholar
• Raungaard B. A prospective, randomized, “all-comers” trial of biodegradable polymer-coated biolimus-eluting stents vs. biocompatible polymer-coated zotarolimus-eluting stents. Presented at the Transcatheter Cardiovascular Therapeutics (TCT). San Francisco, CA, USA; 2013. Available from: www.tctmd.com/show.aspx?id=121393
   Google Scholar
• Galasso G, Piccolo R, Cassese S, et al. Unrestricted use of endeavor resolute zotarolimus-eluting stent in daily clinical practice: a prospective registry. J Invasive Cardiol 2012;24:251-5
   PubMed Web of Science ®Google Scholar
• Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46
   PubMed Web of Science ®Google Scholar
• Jeger R, Pfisterer M, Alber H, et al. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitats Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. Am Heart J 2012;163:136-41; e1
   PubMed Web of Science ®Google Scholar
• Lemesle G, Schurtz G, Delhaye C. Biolimus-eluting stent with biodegradable polymer (Nobori(R)): an overview of recent clinical results, SORT OUT V and COMPARE II trials. Expert Rev Cardiovasc Ther 2013;11:1293-6
   PubMedGoogle Scholar